Impact de la vaccination en pharmacies sur la couverture vaccinale des adultes contre la diphtérie, le tétanos et la coqueluche en France: une étude observationnelle sur les données de santé répertoriées entre 2018 et 2024

Objectif(s) de la recherche et intérêt pour la santé publique

Finalité de l'étude

Objectifs poursuivis

Domaines médicaux investigués

Bénéfices attendus

France has a comprehensive vaccination schedule for adults providing for free regular vaccination against diphtheria, tetanus, and pertussis (Td-IPV/Tdap-IPV), annually against influenza, COVID-19, and shingles in adults older than 65 years of age.
As in many countries, vaccination rates in adults are significantly lower than the rates in children. However, while pertussis vaccination rates are consistently greater than 95% in infants, in 2024 influenza vaccination rates in adults 65 years and older was 54% in France and only 25.3% in those less than 65 and at high-risk. Vaccination against COVID-19 was even lower, at just 21.7% in adults 65 years and older and 8.2% for adults younger than 65 at high-risk of disease. To increase vaccination uptake many European countries allowed vaccination by various healthcare professionals in the last decade, including nurses and pharmacists. In France vaccination by pharmacists (prescribing and injection) started with a pilot phase in two departments in 2017 and was authorized nationwide in late 2022. In 2023, the pharmacists were also authorized to inject certain vaccines in individuals 11 years or older (starting August 8). Hence, 4 scenarios are possible for vaccination: i) prescribed and administered by the pharmacist; ii) prescribed by doctor, delivered and administered by the pharmacist; iii) prescribed by doctor, delivered at the pharmacy, but administration elsewhere; and iv) purchased elsewhere and administered by the pharmacist.
The impact of the implementation of this program on the vaccination coverage particularly Td-IPV/Tdap-IPV vaccination in adults has not yet been determined.
Objective: To determine the change in Td-IPV/Tdap-IPV vaccination (annual number of doses administered and percentage of the population vaccinated in pharmacies and by doctors), in adults (≥ 18 years) before and after the implementation of vaccination by pharmacists in 2023.